FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W57004562> ?p ?o ?g. }

• W57004562 endingPage "3914" @default.
• W57004562 startingPage "3914" @default.
• W57004562 abstract "Abstract Background The dual Src and Abl inhibitor dasatinib has significant in vitro kinase inhibition against wild-type and mutant BCR-ABL, and significant clinical activity in patients with imatinib-resistant lymphoid blast phase CML (CML-LB) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Aim To determine the long-term efficacy of the combination of the hyperCVAD regimen with dasatinib for treating patients with Ph+ ALL. Methods In this phase II trial, patients with newly diagnosed Ph+ ALL received dasatinib 50 mg po bid (or 100 mg daily) for the first 14 days of each of 8 cycles of alternating hyperCVAD and high dose cytarabine and methotrexate (induction/consolidation cycles). After 42 patients, the protocol was amended to give dasatinib 100 mg daily in the first 14 days of the first cycle and then 70 mg daily continuously from the second cycle. Patients in complete remission (CR) continued to receive maintenance dasatinib 50 mg po bid (or 100 mg daily) and vincristine and prednisone monthly for 2 years followed by dasatinib indefinitely. Patients eligible for allogeneic stem cell transplant proceeded to it in first CR. Results 63 patients with untreated Ph+ ALL and 9 patients with 1 or 2 prior cycles of chemotherapy (before Ph+/BCR-ABL+ status was known) have been enrolled in the study from September 2006 to March 2012. Patients have received a median of 6 cycles (range 1-8) of induction/consolidation. Median age is 55 years (range 21 – 80); 46 patients were older than 50 years, Median WBC at diagnosis was 12 x 109/L (range, 0.4 - 658.1 x 109/L). Ten patients had CNS involvement at presentation. All patients are evaluable for assessment of response to induction; 69 (96%) achieved CR after first cycle or were CR at start. 3 patients died before response assessment from infections. 57 of 69 (83%) evaluable patients achieved cytogenetic (CG) CR after 1 cycle; 5 had a major CG response (4 had 5% and one had 15% Ph+), 2 had insufficient metaphases, and 5 are unknown (no CG exam on day 21 marrow). To date, 45 patients (65%) have achieved complete molecular remission (CMR) and another 19 (28%) have achieved a major (but not complete) molecular response (MMR) at a median of 4 weeks from initiation of treatment (range, 2 – 38 weeks). Minimal residual disease assessment by flow cytometry is negative in 65 (94 %) patients at a median of 3 weeks (range, 2-37 weeks). The median time to neutrophil and platelet recovery for cycle 1 is 18 and 22 days and for subsequent cycles is 15 and 20 days. Grade 3 and 4 adverse events have included bleeding (GI, GU, soft tissue and subdural hematomas), pleural effusions, pericardial effusions, reversible rise in creatinine, deep vein thromboses, pulmonary emboli, as well as diarrhea, infections, hypophosphatemia, hypokalemia, hypocalcemia, hyperglycemia, and elevated transaminases. With a median follow up of 48 months in the surviving patients (range 16.5 - 81.5), 36 patients (50%) are alive and 31 (43%) are in CR. Twelve patients have undergone an allogeneic stem cell transplant. Thirty six patients have died [3 at induction, 16 after relapse, 7 post stem cell transplant performed in CR1, and 10 in CR (6 from infections, 1 from unrelated cardiac event, 1 from unrelated cancer, and 2 from an unknown cause)]. The median disease free survival is 31 months (range, 0.3 to 81) and the median overall survival is 44 months (range, 0.2 to 82). Twenty-one patients have relapsed with a median response duration of 16 months (range, 5 - 62) and 16 of them have died. In 6 patients morphological relapse was preceded by flow and molecular relapse. Six relapsed patients had ABL mutations (4 T315I, 1 F359V, and 1 V299L). Conclusion Combination of chemotherapy with dasatinib is effective in achieving long term remissions in patients with newly diagnosed Ph+ ALL. Disclosures: Ravandi: Bristol Myers Squibb: Honoraria, Research Funding. Off Label Use: Use of dasatinib for the frontline therapy of Ph+ ALL. O'Brien:Pharmacyclics: Research Funding. Jabbour:Bristol Myers Squibb: Consultancy, Honoraria. Cortes:Bristol Myers Squibb: Research Funding. Kantarjian:Bristol Myers Squibb: Research Funding." @default.
• W57004562 created "2016-06-24" @default.
• W57004562 creator A5000750846 @default.
• W57004562 creator A5006104041 @default.
• W57004562 creator A5015101485 @default.
• W57004562 creator A5028845635 @default.
• W57004562 creator A5038307470 @default.
• W57004562 creator A5043585566 @default.
• W57004562 creator A5046097970 @default.
• W57004562 creator A5049385583 @default.
• W57004562 creator A5058755419 @default.
• W57004562 creator A5090435894 @default.
• W57004562 date "2013-11-15" @default.
• W57004562 modified "2023-10-15" @default.
• W57004562 title "Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia" @default.
• W57004562 doi "https://doi.org/10.1182/blood.v122.21.3914.3914" @default.
• W57004562 hasPublicationYear "2013" @default.
• W57004562 type Work @default.
• W57004562 sameAs 57004562 @default.
• W57004562 citedByCount "1" @default.
• W57004562 countsByYear W570045622016 @default.
• W57004562 crossrefType "journal-article" @default.
• W57004562 hasAuthorship W57004562A5000750846 @default.
• W57004562 hasAuthorship W57004562A5006104041 @default.
• W57004562 hasAuthorship W57004562A5015101485 @default.
• W57004562 hasAuthorship W57004562A5028845635 @default.
• W57004562 hasAuthorship W57004562A5038307470 @default.
• W57004562 hasAuthorship W57004562A5043585566 @default.
• W57004562 hasAuthorship W57004562A5046097970 @default.
• W57004562 hasAuthorship W57004562A5049385583 @default.
• W57004562 hasAuthorship W57004562A5058755419 @default.
• W57004562 hasAuthorship W57004562A5090435894 @default.
• W57004562 hasConcept C104317684 @default.
• W57004562 hasConcept C126322002 @default.
• W57004562 hasConcept C138626823 @default.
• W57004562 hasConcept C141071460 @default.
• W57004562 hasConcept C2776694085 @default.
• W57004562 hasConcept C2776755627 @default.
• W57004562 hasConcept C2777408962 @default.
• W57004562 hasConcept C2777583451 @default.
• W57004562 hasConcept C2778041864 @default.
• W57004562 hasConcept C2778336483 @default.
• W57004562 hasConcept C2778729363 @default.
• W57004562 hasConcept C2778904597 @default.
• W57004562 hasConcept C2779429289 @default.
• W57004562 hasConcept C2779536868 @default.
• W57004562 hasConcept C2781413609 @default.
• W57004562 hasConcept C2911091166 @default.
• W57004562 hasConcept C3019892230 @default.
• W57004562 hasConcept C55493867 @default.
• W57004562 hasConcept C71924100 @default.
• W57004562 hasConcept C86803240 @default.
• W57004562 hasConcept C90924648 @default.
• W57004562 hasConceptScore W57004562C104317684 @default.
• W57004562 hasConceptScore W57004562C126322002 @default.
• W57004562 hasConceptScore W57004562C138626823 @default.
• W57004562 hasConceptScore W57004562C141071460 @default.
• W57004562 hasConceptScore W57004562C2776694085 @default.
• W57004562 hasConceptScore W57004562C2776755627 @default.
• W57004562 hasConceptScore W57004562C2777408962 @default.
• W57004562 hasConceptScore W57004562C2777583451 @default.
• W57004562 hasConceptScore W57004562C2778041864 @default.
• W57004562 hasConceptScore W57004562C2778336483 @default.
• W57004562 hasConceptScore W57004562C2778729363 @default.
• W57004562 hasConceptScore W57004562C2778904597 @default.
• W57004562 hasConceptScore W57004562C2779429289 @default.
• W57004562 hasConceptScore W57004562C2779536868 @default.
• W57004562 hasConceptScore W57004562C2781413609 @default.
• W57004562 hasConceptScore W57004562C2911091166 @default.
• W57004562 hasConceptScore W57004562C3019892230 @default.
• W57004562 hasConceptScore W57004562C55493867 @default.
• W57004562 hasConceptScore W57004562C71924100 @default.
• W57004562 hasConceptScore W57004562C86803240 @default.
• W57004562 hasConceptScore W57004562C90924648 @default.
• W57004562 hasIssue "21" @default.
• W57004562 hasLocation W570045621 @default.
• W57004562 hasOpenAccess W57004562 @default.
• W57004562 hasPrimaryLocation W570045621 @default.
• W57004562 hasRelatedWork W1994309500 @default.
• W57004562 hasRelatedWork W2044339446 @default.
• W57004562 hasRelatedWork W2070568211 @default.
• W57004562 hasRelatedWork W2102066474 @default.
• W57004562 hasRelatedWork W2112405804 @default.
• W57004562 hasRelatedWork W2544896406 @default.
• W57004562 hasRelatedWork W2552151679 @default.
• W57004562 hasRelatedWork W2566175026 @default.
• W57004562 hasRelatedWork W2588704253 @default.
• W57004562 hasRelatedWork W2592213658 @default.
• W57004562 hasVolume "122" @default.
• W57004562 isParatext "false" @default.
• W57004562 isRetracted "false" @default.
• W57004562 magId "57004562" @default.
• W57004562 workType "article" @default.